DELPHI GENETICS - DELPHI GENETICS YOUR CERTIFIED CDMO PARTNER FOR GMP PLASMID DNA BIOPRODUCTION

Belgien

Office Building Outline icon Tjänsteföretag

DELPHI GENETICS
Web icon
CATALENT TO ACQUIRE DELPHI GENETICS

CATALENT TO ACQUIRE DELPHI GENETICS

Senaste prestation ・ 2021 guov 23

SOMERSET, N.J. and GOSSELIES, BELGIUM – February 23, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility. Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy. https://www.catalent.com/catalent-news/catalent-to-acquire-delphi-genetics-and-launch-us-plasmid-manufacturing-site-to-establish-global-pdna-development-and-manufacturing-capabilities/

Delphi Genetics triples its GMP production capacity

Delphi Genetics triples its GMP production capacity

Senaste prestation ・ 2020 njuk 25 läsa mer Open In New icon

Delphi Genetics announces today that it has received the coveted GMP certificate, issued by the AFMPS, covering its brand new state-of-the-art GMP manufacturing suites. « The approval of these additional three suites allows Delphi Genetics to very significantly enhance its production capacities for plasmid DNA manufacturing and further assist the development of gene therapy candidates and DNA-based therapies », commented François Blondel, Chairman of the board of Directors and CEO. « This approval, and the capacity expansion, are a very significant step forward in the growth of Delphi Genetics. They will allow us to significantly reduce lead time and efficiently support both our existing customer base as well as future customers, mostly active in Gene Therapy using viral vectors », he added.

A new hope for Covid-19 treatment

A new hope for Covid-19 treatment

Senaste prestation ・ 2020 skáb 13 läsa mer Open In New icon

Delphi Genetics announces today that it has obtained highly promising results with its Gene Therapy-based Covid-19 therapeutic candidate in in-vitro experiments. With solid expertise in DNA development and production, Delphi Genetics has developed an innovative approach to treat patients infected by Covid-19. The principle consists in inactivating and destroying the virus in cells where the virus is present. The main objective of this therapy is to cure the disease once patients get infected. The company has three potential candidates, all three being tested with the collaboration of ULiège laboratories and showing promising results on human cells, with the lead candidate being able to 100% inhibit the virus, “far beyond expectations” says Cédric Szpirer, Founder and Executive Director, who leads the project.

Domain icon Tjänsteföretag

DELPHI GENETICS

Rue A. de Saint-Exupéry, 5

6041 Gosselies - Belgien

Momsnr.
Kontakt
Office Building Outline icon
En sida för ditt företag
Ser ni detta? Det gör era potentiella kunder också Registrera er för att bli synliga på europages.

Förfrågan om offerter

Skapa en förfrågan och få flera offerter från verifierade leverantörer.

  • Endast relevanta leverantörer
  • Överensstämmer med dataskyddsförordningen
  • 100% gratis